EUCTR2012-004762-18-DE进行中（未招募）1 期
Controlled, prospective, multicentre, open, randomized study to investigate the contraceptive efficacy, bleeding patterns, metabolic effects, cycle-associated complaints, acceptance, and safety of an oral contraceptive containing 30 µg ethinylestradiol and 150 µg levonorgestrel, in two different regimens of intake (4 extended cycles of 91 days versus 13 conventional cycles of 28 days) in healthy women - Lisa Lang Study
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Madaus GmbH
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Inclusion Criteria
- •1. Subject is informed, has been given ample time and opportunity to think about her participation and has given her written and personally dated informed consent obtained before undergoing any trial-specific procedure
- •2. Subject is a sexually active woman of child-bearing potential, at risk of pregnancy
- •3. Subject seeks contraception and agrees to use study COC as her primary birth control
- •4. Subject is aged between 18 and 35 years at screening (inclusive)
- •5. Subject is able to communicate, participate, and comply with the requirements of the
- •entire study
- •6. Subject is computer literate and able to complete the subject electronic diary
- •7. Subject has given her written specific consent to allow collection and use of contact
- •details for managing alert call.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1623
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Venous thrombosis present or in personal or family history (e.g. deep venous thrombosis, pulmonary embolism) in any body region
- •2. Arterial thrombosis present or in history (e.g. myocardial infarction) or prodromal conditions (e.g. angina pectoris and transient ischaemic attack) in any body region
- •3. Cerebrovascular accident present or in history
- •4. The presence of at least one severe or multiple risk factor(s) for arterial thrombosis, including:
- •diabetes mellitus with vascular symptoms
- •severe dyslipoproteinemia (i.e. screening total serum cholestero=l 240 mg/dl and/or LDL cholesterol =160 mg/dl, as per APT III guidelines , or use of anti-hyperlipidemic agents)
- •valvular heart disease
- •atrial fibrillation
- •5. Known hereditary or acquired predisposition for venous or arterial thrombosis, such as APC-resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant): such predisposing factors will not be specifically investigated, but patient personal and family history in this respect should be collected
- •6. History of other medical conditions associated with vascular AEs (e.g. haemolytic uremic syndrome, chronic inflammatory bowel disease such as Crohn’s disease or ulcerative colitis, sickle cell disease)
- •7. Hypertension defined as repeated measurements of systolic blood pressure >140 and diastolic blood pressure >90 mmHg
- •8. History of hereditary angioedema
- •9. History of migraine with focal neurological symptoms
- •10. Pancreatitis or a history thereof if associated with hypertriglyceridemia
- •11. Presence of hepatic disease (as per abnormal liver function at screening laboratory tests), or history thereof as long as liver function values have not returned to normal
- •12. History of being HIV or Hepatitis C positive
- •13. Presence or history of liver tumours (benign or malignant)
- •14. History of hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- •15. Known or suspected sex-steroid influenced malignancies
- •16. Palpable breast tumours
- •17. Uterine fibroids
- •18. History of cervical cancer
- •19. HPV-positive at screening, PAP smear PAP III or higher
- •20. Known hypersensitivity to the active substances or to any of the excipients of Lisa coated tablets
- •21. BMI >30 kg/m²
- •22. Current smokers up to age 30 (inclusive) smoking more than 10 cigarettes/day
- •23. Subjects up to the age of 30 (inclusive) who consumed more than 10 cigarettes/day and either stopped smoking or reduced smoking to less than 10 cigarettes/day =24 months
- •24. Current smokers (or former smokers who stopped smoking = 24 months) aged more than 30 years
- •25. Desire to become pregnant during study period
- •26. Pregnancy or lactation period
- •27. Undiagnosed vaginal bleeding
- •28. Subjects who have had recent surgical or medical abortion, miscarriage or vaginal or cesarian delivery with less than three normal menstrual cycles prior to study enrolment
- •29. History of having used a contraceptive patch within 3 months prior to enrolment
- •30. History of having received injectable hormone contraceptives or other injectable hormones within the past 10 months prior to study enrolment
- •31. History of having a progestin-releasing intrauterine device in place over the 3 months prior to enrolment
- •32. Routine concomitant use of forms of contraception other than COCs with the exception of occasional condom use during t
研究者
相似试验
进行中（未招募）
不适用
Open, randomized, prospective, controlled, multicentre study to evaluate the efficacy and safety of multiple intraportal applications of liver cell suspension in patients with acute liver failure not eligible for orthotopic liver transplantatioAcute Liver FailureSubgroups of patients with indications falling under ICD classification codes:K70.4, K71, K72, K75, K76, K77MedDRA version: 9.1Level: LLTClassification code 10049844Term: Acute liver failureEUCTR2005-000837-39-DECytonet GmbH & Co. KG90
进行中（未招募）
不适用
Open, randomized, prospective, controlled, multicentre study to evaluate the efficacy and safety of multiple intraportal applications of liver cell suspension in patients with acute liver failure not eligible for orthotopic liver transplantatioAcute Liver FailureSubgroups of patients with indications falling under ICD classification codes:K70.4, K71, K72, K75, K76, K77MedDRA version: 9.1Level: LLTClassification code 10049844Term: Acute liver failureEUCTR2005-000837-39-GBCytonet GmbH & Co. KG90
进行中（未招募）
不适用
Open, randomized, prospective, controlled, multicentre study to evaluate the efficacy and safety of multiple intraportal applications of liver cell suspension in patients with acute liver failure not eligible for orthotopic liver transplantationEstudio abierto, aleatorizado, prospectivo controlado y multicéntrico para la evaluación de la efectividad y la seguridad de la administración reiterada de una suspensión de células hepáticas por la vena porta a pacientes con insuficiencia hepática aguda para los que no es factible efectuar un trasplante ortotópico de hígadoInsuficiencia hepática aguda (IHA) Subgrupos de pacientes con indicationes según ICD classification codes: K70.4, K71, K72, K75, K76, K77MedDRA version: 9.1Level: LLTClassification code 10049844Term: Acute liver failureEUCTR2005-000837-39-ESCytonet GmbH & Co. KG90
进行中（未招募）
1 期
Multi-center, prospective, controlled, randomized, single-blinded study to evaluate the efficacy of vibrotactile neuro-feedback additionally to intake of Ginkgo biloba special extract EGb 761® for the treament of presby vertigo.Presby VertigoMedDRA version: 20.0 Level: PT Classification code 10047340 Term: Vertigo System Organ Class: 10013993 - Ear and labyrinth disordersEUCTR2014-000303-28-DEDr. Willmar Schwabe GmbH & Co. KG120
撤回
4 期
Prospective, Randomized, Controlled, Multicentre, Open Study Releas of Paclitaxel during PTA versus PTA alone for the treatment of de-novo occluded, stenotic or reoccluded, restenotic superficial femoral (SFA) or popliteal arteries.narrowing of the bloodvesselstenosis10003216NL-OMON35958Eurocor GmbH15